Skip to main content

Table 3 Results from the sensitivity analysis

From: Everolimus plus exemestane versus bevacizumab-based chemotherapy for second-line treatment of hormone receptor-positive metastatic breast cancer in Greece: An economic evaluation study

Base case ICER Dominant Low value High Value
Parameter Base case value High value ICER Low value ICER
PFS: EVE plus EXE vs. BEV plus PACL (−50 %; +50 %)   50 % 1,384 € 150 % Dominant
PFS: BEV plus PACL (−50 %; +50 %)   50 % Dominant 150 % Dominant
PFS: EVE plus EXE vs. BEV plus CAPE (−50 %; +50 %)   50 % 26,091 € 150 % Dominant
PFS: BEV plus CAPE (−50 %; +50 %)   50 % Dominant 150 % Dominant
OS: EVE plus EXE vs. BEV plus PACL (−50 %; +50 %)   50 % €11,251 € 150 % Dominant
OS: BEV plus PACL (−50 %; +50 %)   50 % Dominant 150 % Dominant
OS: EVE plus EXE vs. BEV plus CAPE (−50 %; +50 %)   50 % 17,104 € 150 % Dominant
OS: BEV plus CAPE (−50 %; +50 %)   50 % Dominant 150 % 5,876 €
Fixed post-progression survival (6–48 months) 12 6 Dominant 48 Dominant
Utility: pre-progression (0.36; 0.90) 0.773 0.36 Dominant 0.90 Dominant
Utility: post-progression (0.2; 0.97) 0.496 0.22 Dominant 0.97 Dominant
Pre-progression background costs (50 €; 150 €) 95.16 € 50.00 € Dominant 150 € Dominant
Post-progression background costs (500 €; 1500 €) 1,057.41 € 500.00 € Dominant 1,500 € Dominant
Adverse event costs: EVE plus EXE (38 €; 133 €) 62 € 37.89 € Dominant 133 € Dominant
Adverse event costs: BEV plus PACL (4.92 €; 34 €) 5.14 € 4.92 € Dominant 34 € Dominant
Adverse event costs: BEV plus CAPE (0.50 €; 34 €) 1 € 0.50 € Dominant 34 € Dominant
Adverse event disutilities: EVE plus EXE (0.011; 0.04) −0.029 −0.011 Dominant −0.04 Dominant
Adverse event disutilities: BEV plus PACL (0.005; 0.069) 0.027 −0.005 Dominant −0.069 Dominant
Adverse event disutilities: BEV plus CAPE (0.005; 0.069) −0.0031 −0.002 Dominant −0.069 Dominant
Adverse events: unknown disutility assumption (−0.01; −0.10) −0.05 −0.013 Dominant −0.100 Dominant
BOLERO II Central PFS included Without    With Dominant
Fixed post-progression survival applied Without    With Dominant
Dose intensity included Without    With Dominant
Drug cost: EVE plus EXE vs. BEV plus PACL (2000 €; 5000 €) 2,447.75 € 2000 € Dominant 5,000 € 324,159 €
Drug cost: BEV plus PACL (2000 €; 5000 €) 3,806.42 € 2000 € 151,243 € 5,000 € Dominant
Drug cost: EVE plus EXE vs. BEV plus CAPE (2000 €; 5000 €) 2,447.75 2000 € Dominant 5,000 € 4,082,144 €
Drug cost: BEV plus CAPE (2000 €; 5000 €) 3,510.97€ 2000 € 3,539,497 € 5,000 € Dominant
Extrapolation method (EVE plus EXE versus comparator)
Exponential, endpoint (PACL) Dominant
Exponential, endpoint (CAPE) Less effective
Gompertz (PACL) Dominant
Gompertz (CAPE) Less effective
Exponential, curve (PACL) Dominant
Exponential, curve (CAPE) Less effective
Log-logistic(PACL) Dominant
Log-logistic (CAPE) Dominant
  1. EVE: everolimus; EXE: exemestane; BEV: bevacizumab; PACL: paclitaxel; CAPE: capecitabine; ICER: incremental cost effectiveness ratio; PFS: progression free survival; OS : overall survival
Back to article page

BMC Health Services Research

ISSN: 1472-6963

Contact us